Reusable patch and software development kit gives solution providers direct control over data
US FDA cleared the IND application submitted in December 2019
MASIMO: Announces FDA Clearance for Neonatal RD SET® Pulse Oximetry Sensors with Improved Accuracy Specifications
Improved SpO2 Accuracy Now Available for All Patient Populations
SCITECH DEVELOPMENT, LLC: Announces FDA Acceptance of Investigational New Drug (IND) Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma
Company will present at Biotech Showcase™ 2020 on Monday, 01/13/20 at 11:15am PST in San Francisco, CA
LANNETT: Receives FDA Approvals For Two Dosage Strengths Of Butalbital, Acetaminophen And Caffeine Capsules
Lannett Company, Inc. (NYSE: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Butalbital, Acetaminophen and Caffeine (BAC) Capsules, USP, 50mg/300mg/40mg and BAC Capsules, USP, 50 mg/325 mg/40 mg. The two dosage strengths of BAC Capsules, have a combined estimated IQVIA market value of approximately $68.6 million for the 12 months ending October 2019, although actual generic market values are expected to be lower.
The GENOSYL® inhaled nitric oxide approval represents the first and only FDA-approved tankless delivery system and is an important new development in the clinical application of inhaled nitric oxide
Action Represents Another Milestone for the Global Partnership Against Ebola
DAIICHI-SANKYO: ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC), for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.
MolecuLight Receives FDA 510(k) Clearance for its i:X® Handheld Fluorescence Imaging Device for Wound Management
New FDA Approval Extends Label to Including the i:X's Detection of Bacteria and Digital Wound Measurement
UVISION360: Innovative Femtech Medical Device Company Receives Third FDA Clearance; Expands Choices for LUMINELLE System
UVision360 Inc., creators of the patented LUMINELLE® DTx Hysteroscopy System, announced the 510(k) clearance and launch of the latest addition to the LUMINELLE line, the 3mm LUMINELLE® Dx 360˚ Rotatable Disposable Sheath (Diagnostic).
Innovative ventilation system that can be used across health care settings for full range of patients
CEFALY TECHNOLOGY: U.S. Military Gains Quicker Access to Migraine Relief through FDA-Cleared CEFALY Technology
A new partnership between CEFALY Technology and QB Medical puts wearable medical devices in the hands of health care providers and grants active military immediate relief from migraine headaches
OKAMI MEDICAL: Announces Major Milestones: FDA 510(k) Clearance And Key Patent For The LOBO Vascular Occluder
Microcatheter-delivered device designed to provide rapid and focal occlusion of a wide range of peripheral arterial targets
LUYE PHARMA: LY03004 Manufacturing Facility Successfully Passes U.S. FDA Pre-approval Inspection with Zero Observation
LY03004, Luye Pharma's innovative, independently developed Extended-Release Microspheres for Injection has taken another step closer to going on the U.S. market.
Med-botics, LLC Targets Post-operative Death and Harm from Opioids
Suntiva, a trusted advisor to leaders in achieving critical business transformation outcomes, is proud to announce that it recently won ten BPA orders with the U.S. Food and Drug Administration (FDA), with a total value of more than $9 million.